basis	hmg-coa	8	7	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	none	none	none
basis	hmg-coa	8	8	false	none	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	none	none	none
basis	simvastatin	8	7	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
basis	simvastatin	8	7	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
basis	simvastatin	8	8	false	none	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
basis	simvastatin	8	8	false	none	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
basis	simvastatin	8	9	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  		none	36567	none	36567
basis	simvastatin	8	9	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  		none	36567	none	36567
basis	simvastatin	8	10	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  Plasma concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose.  		none	36567	none	36567
basis	simvastatin	8	10	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  Plasma concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose.  		none	36567	none	36567
basis	Simvastatin	8	7	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
basis	Simvastatin	8	7	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
basis	Simvastatin	8	8	false	none	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
basis	Simvastatin	8	8	false	none	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
basis	Simvastatin	8	9	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  		none	36567	none	36567
basis	Simvastatin	8	9	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  		none	36567	none	36567
basis	Simvastatin	8	10	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  Plasma concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose.  		none	36567	none	36567
basis	Simvastatin	8	10	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  Plasma concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose.  		none	36567	none	36567
hmg-coa	cyclosporine	23	21	false	none	Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.  The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  		none	none	none	none
hmg-coa	midazolam	23	25	false	none	The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	none	none	none
hmg-coa	midazolam	24	25	false	none	Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	none	none	none
hmg-coa	creatinine	18	20	false	none	In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.  Clinical study experience in the elderly (n=1 522), suggests that there were no overall differences in safety between elderly and younger patients [see Use in Specific Populations (8.5)].  Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance).  		none	none	none	none
hmg-coa	erythromycin	23	25	false	none	The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	none	none	none
hmg-coa	erythromycin	24	25	false	none	Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	none	none	none
hmg-coa	cholesterol	2	2	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		none	2438	none	D002784
hmg-coa	cholesterol	2	2	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		none	2438	none	D002784
hmg-coa	simvastatin	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Simvastatin is a prodrug and is hydrolyzed to its active 3-hydroxyacid form, simvastatin acid, after administration.  Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		none	36567	none	36567
hmg-coa	simvastatin	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Simvastatin is a prodrug and is hydrolyzed to its active 3-hydroxyacid form, simvastatin acid, after administration.  Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		none	36567	none	36567
hmg-coa	simvastatin	2	2	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		none	36567	none	36567
hmg-coa	simvastatin	2	2	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		none	36567	none	36567
hmg-coa	simvastatin	2	3	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  In addition, simvastatin reduces VLDL and TG and increases HDL-C.  		none	36567	none	36567
hmg-coa	simvastatin	2	3	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  In addition, simvastatin reduces VLDL and TG and increases HDL-C.  		none	36567	none	36567
hmg-coa	simvastatin	18	17	true	positive	Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal.  In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.  		none	36567	none	36567
hmg-coa	simvastatin	18	17	true	positive	Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal.  In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.  		none	36567	none	36567
hmg-coa	simvastatin	18	18	true	positive	In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.  		none	36567	none	36567
hmg-coa	simvastatin	18	18	true	positive	In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.  		none	36567	none	36567
hmg-coa	simvastatin	23	22	false	none	The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  		none	36567	none	36567
hmg-coa	simvastatin	23	22	false	none	The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  		none	36567	none	36567
hmg-coa	simvastatin	23	25	false	none	The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
hmg-coa	simvastatin	23	25	false	none	The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
hmg-coa	simvastatin	7	7	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  		none	36567	none	36567
hmg-coa	simvastatin	7	7	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  		none	36567	none	36567
hmg-coa	simvastatin	7	8	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
hmg-coa	simvastatin	7	8	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
hmg-coa	simvastatin	7	9	true	positive	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  		none	36567	none	36567
hmg-coa	simvastatin	7	9	true	positive	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  		none	36567	none	36567
hmg-coa	simvastatin	8	7	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
hmg-coa	simvastatin	8	7	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
hmg-coa	simvastatin	8	8	false	none	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
hmg-coa	simvastatin	8	8	false	none	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
hmg-coa	simvastatin	8	9	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  		none	36567	none	36567
hmg-coa	simvastatin	8	9	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  		none	36567	none	36567
hmg-coa	simvastatin	8	10	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  Plasma concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose.  		none	36567	none	36567
hmg-coa	simvastatin	8	10	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  Plasma concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose.  		none	36567	none	36567
hmg-coa	simvastatin	24	22	false	none	The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  		none	36567	none	36567
hmg-coa	simvastatin	24	22	false	none	The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  		none	36567	none	36567
hmg-coa	simvastatin	24	25	false	none	Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
hmg-coa	simvastatin	24	25	false	none	Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
hmg-coa	simvastatin	24	26	false	none	Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		none	36567	none	36567
hmg-coa	simvastatin	24	26	false	none	Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		none	36567	none	36567
hmg-coa	Simvastatin	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Simvastatin is a prodrug and is hydrolyzed to its active 3-hydroxyacid form, simvastatin acid, after administration.  Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		none	36567	none	36567
hmg-coa	Simvastatin	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Simvastatin is a prodrug and is hydrolyzed to its active 3-hydroxyacid form, simvastatin acid, after administration.  Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		none	36567	none	36567
hmg-coa	Simvastatin	2	2	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		none	36567	none	36567
hmg-coa	Simvastatin	2	2	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		none	36567	none	36567
hmg-coa	Simvastatin	2	3	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  In addition, simvastatin reduces VLDL and TG and increases HDL-C.  		none	36567	none	36567
hmg-coa	Simvastatin	2	3	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  In addition, simvastatin reduces VLDL and TG and increases HDL-C.  		none	36567	none	36567
hmg-coa	Simvastatin	18	17	true	positive	Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal.  In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.  		none	36567	none	36567
hmg-coa	Simvastatin	18	17	true	positive	Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal.  In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.  		none	36567	none	36567
hmg-coa	Simvastatin	18	18	true	positive	In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.  		none	36567	none	36567
hmg-coa	Simvastatin	18	18	true	positive	In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.  		none	36567	none	36567
hmg-coa	Simvastatin	23	22	false	none	The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  		none	36567	none	36567
hmg-coa	Simvastatin	23	22	false	none	The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  		none	36567	none	36567
hmg-coa	Simvastatin	23	25	false	none	The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
hmg-coa	Simvastatin	23	25	false	none	The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
hmg-coa	Simvastatin	7	7	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  		none	36567	none	36567
hmg-coa	Simvastatin	7	7	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  		none	36567	none	36567
hmg-coa	Simvastatin	7	8	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
hmg-coa	Simvastatin	7	8	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
hmg-coa	Simvastatin	7	9	true	positive	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  		none	36567	none	36567
hmg-coa	Simvastatin	7	9	true	positive	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  		none	36567	none	36567
hmg-coa	Simvastatin	8	7	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
hmg-coa	Simvastatin	8	7	false	none	12.3 Pharmacokinetics    Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding â-hydroxyacid, a potent inhibitor of HMG-CoA reductase.  Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
hmg-coa	Simvastatin	8	8	false	none	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
hmg-coa	Simvastatin	8	8	false	none	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  		none	36567	none	36567
hmg-coa	Simvastatin	8	9	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  		none	36567	none	36567
hmg-coa	Simvastatin	8	9	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  		none	36567	none	36567
hmg-coa	Simvastatin	8	10	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  Plasma concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose.  		none	36567	none	36567
hmg-coa	Simvastatin	8	10	true	positive	Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the â-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin.  Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.  Plasma concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose.  		none	36567	none	36567
hmg-coa	Simvastatin	24	22	false	none	The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  		none	36567	none	36567
hmg-coa	Simvastatin	24	22	false	none	The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  		none	36567	none	36567
hmg-coa	Simvastatin	24	25	false	none	Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
hmg-coa	Simvastatin	24	25	false	none	Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
hmg-coa	Simvastatin	24	26	false	none	Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		none	36567	none	36567
hmg-coa	Simvastatin	24	26	false	none	Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		none	36567	none	36567
hmg-coa	p450	23	25	false	none	The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.  Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	none	none	none
hmg-coa	p450	24	25	false	none	Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].  In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	none	none	none
cyclosporine	creatinine	21	20	true	positive	Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance).  Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.  		none	none	none	none
cyclosporine	simvastatin	21	22	true	positive	Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.  The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  		none	36567	none	36567
cyclosporine	simvastatin	21	22	true	positive	Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.  The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  		none	36567	none	36567
cyclosporine	Simvastatin	21	22	true	positive	Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.  The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  		none	36567	none	36567
cyclosporine	Simvastatin	21	22	true	positive	Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.  The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  		none	36567	none	36567
midazolam	digoxin	25	27	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	none	none	none
midazolam	erythromycin	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	none	none	none
midazolam	simvastatin	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
midazolam	simvastatin	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
midazolam	simvastatin	25	27	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
midazolam	simvastatin	25	27	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
midazolam	simvastatin	25	26	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		none	36567	none	36567
midazolam	simvastatin	25	26	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		none	36567	none	36567
midazolam	Simvastatin	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
midazolam	Simvastatin	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
midazolam	Simvastatin	25	27	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
midazolam	Simvastatin	25	27	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
midazolam	Simvastatin	25	26	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		none	36567	none	36567
midazolam	Simvastatin	25	26	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		none	36567	none	36567
midazolam	p450	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	none	none	none
creatinine	simvastatin	20	18	false	none	In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.  Clinical study experience in the elderly (n=1 522), suggests that there were no overall differences in safety between elderly and younger patients [see Use in Specific Populations (8.5)].  Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance).  		none	36567	none	36567
creatinine	simvastatin	20	18	false	none	In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.  Clinical study experience in the elderly (n=1 522), suggests that there were no overall differences in safety between elderly and younger patients [see Use in Specific Populations (8.5)].  Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance).  		none	36567	none	36567
creatinine	simvastatin	20	22	true	positive	Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance).  Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.  The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  		none	36567	none	36567
creatinine	simvastatin	20	22	true	positive	Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance).  Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.  The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  		none	36567	none	36567
creatinine	Simvastatin	20	18	false	none	In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.  Clinical study experience in the elderly (n=1 522), suggests that there were no overall differences in safety between elderly and younger patients [see Use in Specific Populations (8.5)].  Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance).  		none	36567	none	36567
creatinine	Simvastatin	20	18	false	none	In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age.  Clinical study experience in the elderly (n=1 522), suggests that there were no overall differences in safety between elderly and younger patients [see Use in Specific Populations (8.5)].  Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance).  		none	36567	none	36567
creatinine	Simvastatin	20	22	true	positive	Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance).  Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.  The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  		none	36567	none	36567
creatinine	Simvastatin	20	22	true	positive	Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance).  Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.  The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.  		none	36567	none	36567
digoxin	erythromycin	27	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	none	none	none
digoxin	simvastatin	27	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
digoxin	simvastatin	27	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
digoxin	simvastatin	27	27	true	positive	Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
digoxin	simvastatin	27	27	true	positive	Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
digoxin	simvastatin	27	26	false	none	This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
digoxin	simvastatin	27	26	false	none	This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
digoxin	Simvastatin	27	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
digoxin	Simvastatin	27	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
digoxin	Simvastatin	27	27	true	positive	Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
digoxin	Simvastatin	27	27	true	positive	Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
digoxin	Simvastatin	27	26	false	none	This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
digoxin	Simvastatin	27	26	false	none	This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
digoxin	p450	27	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	none	none	none
erythromycin	simvastatin	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
erythromycin	simvastatin	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
erythromycin	simvastatin	25	27	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
erythromycin	simvastatin	25	27	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
erythromycin	simvastatin	25	26	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		none	36567	none	36567
erythromycin	simvastatin	25	26	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		none	36567	none	36567
erythromycin	Simvastatin	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
erythromycin	Simvastatin	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	36567	none	36567
erythromycin	Simvastatin	25	27	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
erythromycin	Simvastatin	25	27	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		none	36567	none	36567
erythromycin	Simvastatin	25	26	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		none	36567	none	36567
erythromycin	Simvastatin	25	26	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		none	36567	none	36567
erythromycin	p450	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		none	none	none	none
cholesterol	simvastatin	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Simvastatin is a prodrug and is hydrolyzed to its active 3-hydroxyacid form, simvastatin acid, after administration.  Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		2438	36567	D002784	36567
cholesterol	simvastatin	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Simvastatin is a prodrug and is hydrolyzed to its active 3-hydroxyacid form, simvastatin acid, after administration.  Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		2438	36567	D002784	36567
cholesterol	simvastatin	2	2	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		2438	36567	D002784	36567
cholesterol	simvastatin	2	2	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		2438	36567	D002784	36567
cholesterol	simvastatin	2	3	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  In addition, simvastatin reduces VLDL and TG and increases HDL-C.  		2438	36567	D002784	36567
cholesterol	simvastatin	2	3	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  In addition, simvastatin reduces VLDL and TG and increases HDL-C.  		2438	36567	D002784	36567
cholesterol	Simvastatin	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Simvastatin is a prodrug and is hydrolyzed to its active 3-hydroxyacid form, simvastatin acid, after administration.  Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		2438	36567	D002784	36567
cholesterol	Simvastatin	2	1	false	none	12 CLINICAL PHARMACOLOGY    12.1 Mechanism of Action    Simvastatin is a prodrug and is hydrolyzed to its active 3-hydroxyacid form, simvastatin acid, after administration.  Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		2438	36567	D002784	36567
cholesterol	Simvastatin	2	2	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		2438	36567	D002784	36567
cholesterol	Simvastatin	2	2	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  		2438	36567	D002784	36567
cholesterol	Simvastatin	2	3	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  In addition, simvastatin reduces VLDL and TG and increases HDL-C.  		2438	36567	D002784	36567
cholesterol	Simvastatin	2	3	false	none	Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.  In addition, simvastatin reduces VLDL and TG and increases HDL-C.  		2438	36567	D002784	36567
simvastatin	p450	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		36567	none	36567	none
simvastatin	p450	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		36567	none	36567	none
simvastatin	p450	27	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		36567	none	36567	none
simvastatin	p450	27	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		36567	none	36567	none
simvastatin	p450	26	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		36567	none	36567	none
simvastatin	p450	26	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		36567	none	36567	none
Simvastatin	p450	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		36567	none	36567	none
Simvastatin	p450	25	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  		36567	none	36567	none
Simvastatin	p450	27	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		36567	none	36567	none
Simvastatin	p450	27	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.  		36567	none	36567	none
Simvastatin	p450	26	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		36567	none	36567	none
Simvastatin	p450	26	25	false	none	In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.  This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.  		36567	none	36567	none
